Report Cover

Europe Antiviral Drugs Market Size By Age Group, By Drug Class, By Indication, By Type, Research Report, Country Outlook, Price Trends, Growth Prospects, Competitive Industry Share & Forecasts, 2021 - 2027


Rising cases of viral infection, including hepatitis, coronavirus, AIDS and respiratory syncytial virus (RSV) infection will underscore Europe antiviral drugs market value. Soaring geriatric demographics will further augment the product adoption. Prominently, elderly population suffering from hypertension, diabetes and CVD are more prone to coronavirus.
An upsurge in the number of drug approvals will augur well for the industry size expansion. The application of anti-viral drugs has played a pivotal role in reducing infection and viral load. Moreover, rising marketing authorization for COVID-19 prescription drugs will further the market presence of drugs. Russia, for instance, gave a green signal for the first COVID-19 drug in September 2020 for sale in pharmacies. According to an estimate, Europe antiviral drugs market size will surpass USD 8.7 billion by 2027.
Expanding foothold of reverse transcriptase inhibitors following the rise in HIV population will bolster the manufacturing of antiviral drugs in the U.K., Italy, Germany and France. Moreover, rise in FDA approvals has further added impetus towards the product portfolio expansion of the drug. The reverse transcriptase inhibitors segment witnessed over 40% market share in 2020 and will thrive with increasing footprint across the end-use applications.
End-users are expected to show increased traction towards branded drugs as they have original drug class which are manufactured and developed through original pharmaceutical company. Besides, bullish demand for branded drugs and an upsurge in research and development activities have come in the backdrop of increased efficacy and specificity. 
A meteoric rise in hepatitis cases has prompted the manufacturers to up the production of antiviral drugs. According to the WHO, hepatitis incidence rate among the EU members stands at 8.7 per 100,000.  Europe antiviral drugs market revenue from the hepatitis segment surpassed USD 2 billion in 2020 and will grow owing to rise in drug approval across the region.
With a spike in geriatric population across the region, industry participants are poised to inject funds in the landscape. According to the Eurostat, over 20% of the EU-27 population are aged 65 years or over. The market share from the geriatric segment in Europe will grow at a considerable rate by 2027.
The U.K. is likely to come up as a happy hunting ground in the wake of expansion of healthcare facilities and presence of large patient pool. Prominently, thriving R&D activities and presence of leading companies will underscore the business outlook. Robust approval of drugs and rising drug trial will pan well for industry participants vying to expand their portfolios. Specifically, the U.K. confirmed the roll out of new trial in May 2020 focusing on COVID-19 patients. 
Stakeholders will expand their presence in Germany on the heels of use of anti-viral medicines for the treatment of infectious diseases, including hepatitis and coronavirus. Notably, surge in baby boomer population has further augmented the demand for anti-viral therapeutics. The American Association of Retired Persons claims that Germany is among the five super-aged societies in the globe. The number of people aged 65 and older is forecast to be pegged at 24 million by 2050 in Germany. 
Key industry players in the landscape are GlaxoSmithKline, plc, AstraZeneca, Johnson & Johnson, Gilead Science and Merck & Co., among others. These leading companies will further their product lines and up their focus on mergers & acquisitions. Illustratively, Gilead was approached by AstraZeneca for a merger in June 2020.
Report Content

Chapter 1   Methodology

1.1    Market definitions

1.2    Forecast assumptions

1.3    Data sources

1.3.1    Secondary

1.3.1.1    Paid sources

1.3.1.2    Unpaid sources

1.3.2    Primary

Chapter 2   Market Summary

2.1    Europe anti-viral drugs industry summary, 2016 - 2027

2.1.1    Country trends

2.1.2    Drug class trends

2.1.3    Indication trends

2.1.4    Type trends

2.1.5    Age group trends

Chapter 3   Market Analysis

3.1    Industry segmentation

3.2    Industry outlook, 2016 - 2027

3.3    Major factor analysis

3.3.1    Growth drivers

3.3.1.1    Increasing prevalence of viral infection

3.3.1.2    Presence of large geriatric population

3.3.1.3    Increasing research and development activities in the field of Anti-viral drugs

3.3.2    Industry pitfalls and challenges

3.3.2.1    Rising awareness about preventive drug treatment

3.3.2.2    Presence of generics

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter's analysis

3.6    Competitive review, 2020

3.7    PEST analysis

Chapter 4   Europe Anti-viral Drugs Market, By Drug Class

4.1    Market trends

4.2    DNA Polymerase Inhibitors

4.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.3    Reverse Transcriptase Inhibitors

4.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.4    Protease Inhibitors

4.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.5    Neuraminidase Inhibitors

4.5.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

4.6    Others

4.6.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 5   Europe Anti-viral Drugs Market, By Indication

5.1    Market trends

5.2    Influenza

5.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.3    HIV AIDS

5.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.4    Hepatitis

5.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.5    Herpes Simplex Virus (HSV)

5.5.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.6    Coronavirus infection

5.6.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

5.7    Others

5.7.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 6   Europe Anti-viral Drug Market, By Type

6.1    Market trends

6.2    Branded

6.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

6.3    Generic

6.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 7   Europe Anti-viral Drugs Market, By Age Group

7.1    Market trends

7.2    Adult

7.2.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.3    Pediatric

7.3.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

7.4    Geriatric

7.4.1    Market estimates and forecast, by country, 2016 - 2027 (USD Million)

Chapter 8   Europe Anti-viral Drugs Market, By Country

8.1    Market trends

8.2    Germany

8.2.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.2.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.2.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.2.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.3    UK

8.3.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.3.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.3.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.3.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.4    France

8.4.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.4.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.4.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.4.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.5    Spain

8.5.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.5.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.5.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.5.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.6    Italy

8.6.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.6.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.6.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.6.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.7    Russia

8.7.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.7.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.7.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.7.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.8    Poland

8.8.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.8.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.8.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.8.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.9    Switzerland

8.9.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.9.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.9.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.9.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.10    The Netherlands

8.10.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.10.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.10.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.10.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

8.11    Sweden

8.11.1    Market estimates and forecast, by drug class, 2016 - 2027 (USD Million)

8.11.2    Market estimates and forecast, by indication, 2016 - 2027 (USD Million)

8.11.3    Market estimates and forecast, by type, 2016 - 2027 (USD Million)

8.11.4    Market estimates and forecast, by age group, 2016 - 2027 (USD Million)

Chapter 9   Company Profiles

9.1    Gilead Science, Inc

9.1.1    Business overview

9.1.2    Financial data

9.1.3    Drug class landscape

9.1.4    Strategic outlook

9.2    Johnson & Johnson

9.2.1    Business overview

9.2.2    Financial data

9.2.3    Drug class landscape

9.2.4    Strategic outlook

9.3    AstraZeneca

9.3.1    Business overview

9.3.2    Financial data

9.3.3    Drug class landscape

9.3.4    Strategic outlook

9.4    GlaxoSmithKline

9.4.1    Business overview

9.4.2    Financial data

9.4.3    Drug class landscape

9.4.4    Strategic outlook

9.5    Abbvie, Inc

9.5.1    Business overview

9.5.2    Financial data

9.5.3    Drug class landscape

9.5.4    Strategic outlook

9.6    Merck & Co.,

9.6.1    Business overview

9.6.2    Financial data

9.6.3    Drug class landscape

9.6.4    Strategic outlook

9.7    Bristol Myers Squib

9.7.1    Business overview

9.7.2    Financial data

9.7.3    Drug class landscape

9.7.4    Strategic outlook

9.8    Mylan N.V.

9.8.1    Business overview

9.8.2    Financial data

9.8.3    Drug class landscape

9.8.4    Strategic outlook


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:
Publisher: Graphical Research
Chat with us